# BONE: STAR (Switching to TAF Based Anti-Retroviral Therapy) Study

> **NCT03916328** · PHASE4 · UNKNOWN · sponsor: **MU-JHU CARE** · enrollment: 330 (estimated)

## Conditions studied

- Bone Loss

## Interventions

- **DRUG:** B/F/TAF
- **DRUG:** TDF/3TC/EFV or DTG or NVP
- **OTHER:** DMPA

## Key facts

- **NCT ID:** NCT03916328
- **Lead sponsor:** MU-JHU CARE
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-03
- **Primary completion:** 2024-03-31
- **Final completion:** 2024-03-31
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2023-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03916328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03916328, "BONE: STAR (Switching to TAF Based Anti-Retroviral Therapy) Study". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03916328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*